Treatment

Treatment of polycythemia vera (PV) is shifting from focusing only on hematocrit control to a broader approach that also targets white blood cells, platelets, and symptoms. Data from large studies like REVEAL study show that higher levels of white blood cells and neutrophils, not just hematocrit, are linked to increased risk of blood clots. Keeping […]

After Prior Treatments A phase 1/2 study (2870-001/KL264-01) reports that sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate, shows strong antitumor activity in patients with advanced or metastatic urothelial carcinoma who have already failed standard treatments. Among 49 heavily pretreated patients, the overall response rate was 31%, with higher responses (50%) in those who had only one

Five-year results from a phase 3 study show that tebentafusp-tebn significantly improves survival in patients with HLA-A*02:01–positive metastatic uveal melanoma. Patients treated with tebentafusp lived a median of 21.6 months, compared with 16.9 months for those receiving standard therapies such as pembrolizumab, ipilimumab, or dacarbazine. At five years, 16% of patients in the tebentafusp group were

Researchers are reporting major progress in targeting KRAS, a cancer-driving protein long considered “undruggable.” Mutations in KRAS keep cells stuck in a constant growth mode, contributing to some of the most aggressive cancers, including pancreatic cancer. Instead of simply trying to block KRAS activity, scientists are now developing “degrader” drugs that label the mutant protein

Mevrometostat, an experimental EZH2 inhibitor, is showing strong potential for treating metastatic castration-resistant prostate cancer by blocking “lineage plasticity,” a process that allows cancer cells to change and resist hormone therapy. When combined with enzalutamide, the treatment significantly improved outcomes in early studies. In a phase 1 trial, the combination nearly doubled median radiographic progression-free

Researchers have developed an experimental nanotherapy aimed at overcoming two major challenges in treating glioblastoma: the blood-brain barrier and drug resistance. The approach uses tiny lipid particles called liposomes to carry two existing drugs—everolimus (or rapamycin) and vinorelbine—directly to tumor cells. By delivering both drugs together, the therapy blocks tumor growth pathways and prevents cancer

The Phase 3 TANGENT trial showed that emactuzumab significantly improves outcomes for patients with tenosynovial giant cell tumor compared to placebo. At six months, patients receiving the drug had higher tumor response rates and greater reductions in tumor size. Many also experienced quick and lasting improvements in physical function, including less pain, better movement, and

The phase 3 RASolute 302 trial shows that daraxonrasib (RMC-6236) significantly improves survival in patients with previously treated metastatic pancreatic cancer compared with standard chemotherapy. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy, representing a 60% reduction in the risk of death. The drug also improved

Results show that cadonilimab, a bispecific antibody, combined with chemotherapy is highly effective as a first-line treatment for advanced or recurrent endometrial cancer. In the study of 41 evaluable patients, 78% experienced significant tumor shrinkage and 97.6% achieved disease control, meaning most patients had either tumor reduction or stable disease. The median progression-free survival was

Data shows that niraparib (Zejula) maintenance therapy for ovarian cancer is generally safe and manageable outside of clinical trials. The study followed 218 patients for a median of 22.6 months and found that blood-related side effects were common but usually mild to moderate. These included low platelets (60.1%), anemia (58.7%), and low white blood cells